Cargando…
Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
PURPOSE: Malignant pleural mesothelioma (MPM) is an aggressive tumor characterized by poor prognosis. Its incidence is steadily increasing due to widespread asbestos exposure. There is still no effective therapy for MPM. Pemetrexed (Pe) is one of the few chemotherapeutic agents approved for advanced...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361319/ https://www.ncbi.nlm.nih.gov/pubmed/30774332 http://dx.doi.org/10.2147/IJN.S186344 |
_version_ | 1783392668843245568 |
---|---|
author | Cova, Emanuela Pandolfi, Laura Colombo, Miriam Frangipane, Vanessa Inghilleri, Simona Morosini, Monica Mrakic-Sposta, Simona Moretti, Sarah Monti, Manuela Pignochino, Ymera Benvenuti, Silvia Prosperi, Davide Stella, Giulia Morbini, Patrizia Meloni, Federica |
author_facet | Cova, Emanuela Pandolfi, Laura Colombo, Miriam Frangipane, Vanessa Inghilleri, Simona Morosini, Monica Mrakic-Sposta, Simona Moretti, Sarah Monti, Manuela Pignochino, Ymera Benvenuti, Silvia Prosperi, Davide Stella, Giulia Morbini, Patrizia Meloni, Federica |
author_sort | Cova, Emanuela |
collection | PubMed |
description | PURPOSE: Malignant pleural mesothelioma (MPM) is an aggressive tumor characterized by poor prognosis. Its incidence is steadily increasing due to widespread asbestos exposure. There is still no effective therapy for MPM. Pemetrexed (Pe) is one of the few chemotherapeutic agents approved for advanced-stage disease, although the objective response to the drug is limited. The use of gold nanoparticles (GNPs) as a drug delivery system promises several advantages, including specific targeting of malignant cells, with increased intracellular drug accumulation and reduced systemic toxicity, and, in the case of MPM, direct treatment administration into the pleural space. This study aims at exploring CD146 as a potential MPM cell-specific target for engineered Pe-loaded GNPs and to assess their effectiveness in inhibiting MPM cell line growth. METHODS: MPM cell lines and primary cultures obtained by pleural effusions from MPM patients were assayed for CD146 expression by flow cytometry. Internalization by MPM cell lines of fluorescent dye-marked GNPs decorated with a monoclonal anti CD146 coated GNPs (GNP-HC) was proven by confocal microscopy. The effects of anti CD146 coated GNPs loaded with Pe (GNP-HCPe) on MPM cell lines were evaluated by cell cycle (flow cytometry), viability (MTT test), clonogenic capacity (soft agar assay), ROS production (electric paramagnetic resonance), motility (wound healing assay), and apoptosis (flow cytometry). RESULTS: GNP-HC were selectively uptaken by MPM cells within 1 hour. MPM cell lines were blocked in the S cell cycle phase in the presence of GNP-HCPe. Both cell viability and motility were significantly affected by nanoparticle treatment compared to Pe. Apoptotic rate and ROS production were significantly higher in the presence of nanoparticles. Clonogenic capacity was completely inhibited following nanoparticle internalization. CONCLUSION: GNP-HCPe treatment displays in vitro antineoplastic action and is more effective than Pe alone in inhibiting MPM cell line malignant phenotype. The innovative use of specifically targeted GNPs opens the perspective of local intrapleural administration to avoid normal cell toxicity and enhance chemotherapy efficacy. |
format | Online Article Text |
id | pubmed-6361319 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-63613192019-02-15 Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study Cova, Emanuela Pandolfi, Laura Colombo, Miriam Frangipane, Vanessa Inghilleri, Simona Morosini, Monica Mrakic-Sposta, Simona Moretti, Sarah Monti, Manuela Pignochino, Ymera Benvenuti, Silvia Prosperi, Davide Stella, Giulia Morbini, Patrizia Meloni, Federica Int J Nanomedicine Original Research PURPOSE: Malignant pleural mesothelioma (MPM) is an aggressive tumor characterized by poor prognosis. Its incidence is steadily increasing due to widespread asbestos exposure. There is still no effective therapy for MPM. Pemetrexed (Pe) is one of the few chemotherapeutic agents approved for advanced-stage disease, although the objective response to the drug is limited. The use of gold nanoparticles (GNPs) as a drug delivery system promises several advantages, including specific targeting of malignant cells, with increased intracellular drug accumulation and reduced systemic toxicity, and, in the case of MPM, direct treatment administration into the pleural space. This study aims at exploring CD146 as a potential MPM cell-specific target for engineered Pe-loaded GNPs and to assess their effectiveness in inhibiting MPM cell line growth. METHODS: MPM cell lines and primary cultures obtained by pleural effusions from MPM patients were assayed for CD146 expression by flow cytometry. Internalization by MPM cell lines of fluorescent dye-marked GNPs decorated with a monoclonal anti CD146 coated GNPs (GNP-HC) was proven by confocal microscopy. The effects of anti CD146 coated GNPs loaded with Pe (GNP-HCPe) on MPM cell lines were evaluated by cell cycle (flow cytometry), viability (MTT test), clonogenic capacity (soft agar assay), ROS production (electric paramagnetic resonance), motility (wound healing assay), and apoptosis (flow cytometry). RESULTS: GNP-HC were selectively uptaken by MPM cells within 1 hour. MPM cell lines were blocked in the S cell cycle phase in the presence of GNP-HCPe. Both cell viability and motility were significantly affected by nanoparticle treatment compared to Pe. Apoptotic rate and ROS production were significantly higher in the presence of nanoparticles. Clonogenic capacity was completely inhibited following nanoparticle internalization. CONCLUSION: GNP-HCPe treatment displays in vitro antineoplastic action and is more effective than Pe alone in inhibiting MPM cell line malignant phenotype. The innovative use of specifically targeted GNPs opens the perspective of local intrapleural administration to avoid normal cell toxicity and enhance chemotherapy efficacy. Dove Medical Press 2019-01-23 /pmc/articles/PMC6361319/ /pubmed/30774332 http://dx.doi.org/10.2147/IJN.S186344 Text en © 2019 Cova et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Cova, Emanuela Pandolfi, Laura Colombo, Miriam Frangipane, Vanessa Inghilleri, Simona Morosini, Monica Mrakic-Sposta, Simona Moretti, Sarah Monti, Manuela Pignochino, Ymera Benvenuti, Silvia Prosperi, Davide Stella, Giulia Morbini, Patrizia Meloni, Federica Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study |
title | Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study |
title_full | Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study |
title_fullStr | Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study |
title_full_unstemmed | Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study |
title_short | Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study |
title_sort | pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361319/ https://www.ncbi.nlm.nih.gov/pubmed/30774332 http://dx.doi.org/10.2147/IJN.S186344 |
work_keys_str_mv | AT covaemanuela pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy AT pandolfilaura pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy AT colombomiriam pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy AT frangipanevanessa pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy AT inghillerisimona pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy AT morosinimonica pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy AT mrakicspostasimona pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy AT morettisarah pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy AT montimanuela pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy AT pignochinoymera pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy AT benvenutisilvia pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy AT prosperidavide pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy AT stellagiulia pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy AT morbinipatrizia pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy AT melonifederica pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy |